Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) EBIT Margin (2022 - 2025)

Historic EBIT Margin for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to 163.66%.

  • ARS Pharmaceuticals' EBIT Margin rose 8879800.0% to 163.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 63.59%, marking a year-over-year increase of 22925600.0%. This contributed to the annual value of 3.46% for FY2024, which is 2250632100.0% up from last year.
  • ARS Pharmaceuticals' EBIT Margin amounted to 163.66% in Q3 2025, which was up 8879800.0% from 302.95% recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' EBIT Margin ranged from a high of 54.51% in Q4 2024 and a low of 206030.0% during Q2 2023
  • Moreover, its 4-year median value for EBIT Margin was 1070.74% (2022), whereas its average is 28230.81%.
  • Per our database at Business Quant, ARS Pharmaceuticals' EBIT Margin plummeted by 2000000000bps in 2023 and then soared by 2000000000bps in 2024.
  • Over the past 4 years, ARS Pharmaceuticals' EBIT Margin (Quarter) stood at 3507.94% in 2022, then crashed by -5773bps to 206030.0% in 2023, then soared by 100bps to 54.51% in 2024, then plummeted by -400bps to 163.66% in 2025.
  • Its EBIT Margin was 163.66% in Q3 2025, compared to 302.95% in Q2 2025 and 466.29% in Q1 2025.